CLIR vs. NAUT, KEQU, FEIM, SEER, RPID, AKYA, INTT, MASS, OWLT, and OPTX
Should you be buying ClearSign Technologies stock or one of its competitors? The main competitors of ClearSign Technologies include Nautilus Biotechnology (NAUT), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Seer (SEER), Rapid Micro Biosystems (RPID), Akoya Biosciences (AKYA), inTEST (INTT), 908 Devices (MASS), Owlet (OWLT), and Syntec Optics (OPTX). These companies are all part of the "measuring and control equipment" industry.
ClearSign Technologies vs.
Nautilus Biotechnology (NASDAQ:NAUT) and ClearSign Technologies (NASDAQ:CLIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
ClearSign Technologies has higher revenue and earnings than Nautilus Biotechnology. ClearSign Technologies is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
ClearSign Technologies received 148 more outperform votes than Nautilus Biotechnology when rated by MarketBeat users. Likewise, 41.76% of users gave ClearSign Technologies an outperform vote while only 19.05% of users gave Nautilus Biotechnology an outperform vote.
In the previous week, Nautilus Biotechnology had 2 more articles in the media than ClearSign Technologies. MarketBeat recorded 2 mentions for Nautilus Biotechnology and 0 mentions for ClearSign Technologies. Nautilus Biotechnology's average media sentiment score of 0.00 equaled ClearSign Technologies'average media sentiment score.
Nautilus Biotechnology has a net margin of 0.00% compared to ClearSign Technologies' net margin of -118.93%. Nautilus Biotechnology's return on equity of -28.85% beat ClearSign Technologies' return on equity.
50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 24.0% of ClearSign Technologies shares are owned by institutional investors. 40.5% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 16.9% of ClearSign Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Nautilus Biotechnology has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, ClearSign Technologies has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Nautilus Biotechnology presently has a consensus price target of $3.58, suggesting a potential upside of 132.68%. ClearSign Technologies has a consensus price target of $6.00, suggesting a potential upside of 650.00%. Given ClearSign Technologies' stronger consensus rating and higher probable upside, analysts plainly believe ClearSign Technologies is more favorable than Nautilus Biotechnology.
Summary
Nautilus Biotechnology beats ClearSign Technologies on 8 of the 15 factors compared between the two stocks.
Get ClearSign Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearSign Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:CLIR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CLIR Stock Alerts